R
Roberto Ria
Researcher at University of Bari
Publications - 215
Citations - 10631
Roberto Ria is an academic researcher from University of Bari. The author has contributed to research in topics: Multiple myeloma & Angiogenesis. The author has an hindex of 48, co-authored 198 publications receiving 9735 citations. Previous affiliations of Roberto Ria include University of Brescia & University of Bologna.
Papers
More filters
Journal Article
Bone marrow angiogenesis and progression in multiple myeloma
Roberto Ria,Antonia Reale,Annunziata De Luisi,Arianna Ferrucci,Michele Moschetta,Angelo Vacca +5 more
TL;DR: Since angiogenesis proceeds in step with the enlargement of plasma cell tumours and the activity phase in MM, its measurement could be a useful prognostic marker in patients with plasma cell proliferative disorders.
Journal ArticleDOI
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
Angelo Vacca,Domenico Ribatti,Marco Presta,M Minischetti,Monica Iurlaro,Roberto Ria,Adriana Albini,Federico Bussolino,Franco Dammacco +8 more
TL;DR: Findings indicate that the progression of plasma cell tumors is accompanied by an increase of bone marrow neovascularization, which is dependent, at least in part, by FGF-2 and MMP-2 production.
Journal ArticleDOI
Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo
Domenico Ribatti,Marco Presta,Marco Presta,Angelo Vacca,Angelo Vacca,Roberto Ria,Roberto Ria,Roberta Giuliani,Roberta Giuliani,Patrizia Dell'Era,Patrizia Dell'Era,Beatrice Nico,Beatrice Nico,Luisa Roncali,Luisa Roncali,Franco Dammacco,Franco Dammacco +16 more
TL;DR: The ability of Epo to interact directly with endothelial cells and to elicit an angiogenic response in vitro and in vivo is demonstrated and thus acts as a bona fide directAngiogenic factor.
Journal ArticleDOI
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo,Sara Bringhen,Davide Rossi,Maide Cavalli,Alessandra Larocca,Roberto Ria,Massimo Offidani,Francesca Patriarca,Chiara Nozzoli,Tommasina Guglielmelli,Giulia Benevolo,Vincenzo Callea,Luca Baldini,Fortunato Morabito,Mariella Grasso,Giovanna Leonardi,Manuela Rizzo,Antonietta Falcone,Daniela Gottardi,Vittorio Montefusco,Pellegrino Musto,Maria Teresa Petrucci,Giovannino Ciccone,Mario Boccadoro +23 more
TL;DR: VMPT followed by VT as maintenance was superior to VMP alone in patients with multiple myeloma who are ineligible for autologous stem-cell transplantation.
Journal ArticleDOI
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Sara Bringhen,Alessandra Larocca,Davide Rossi,Maide Cavalli,Mariella Genuardi,Roberto Ria,Silvia Gentili,Francesca Patriarca,Chiara Nozzoli,Anna Levi,Tommasina Guglielmelli,Giulia Benevolo,Vincenzo Callea,Vincenzo Rizzo,Clotilde Cangialosi,Pellegrino Musto,Luca De Rosa,Anna Marina Liberati,Mariella Grasso,Antonietta Falcone,Andrea Evangelista,Michele Cavo,Gianluca Gaidano,Mario Boccadoro,Antonio Palumbo +24 more
TL;DR: The protocol was amended and patients in both arms received once-weekly instead of the initial twice-weekly bortezomib infusions to decrease neurologic toxicities, and an improvement in safety did not appear to affect efficacy.